Literature DB >> 23768618

Successful PGD for late infantile neuronal ceroid lipofuscinosis achieved by combined chromosome and TPP1 gene analysis.

Jiandong Shen1, David Stephen Cram, Wei Wu, Lingbo Cai, Xiaoyu Yang, Xueping Sun, Yugui Cui, Jiayin Liu.   

Abstract

Late infantile neuronal ceroid lipofuscinosis (NCL-2) is a severe debilitating autosomal recessive disease caused by mutations in TPP1. There are no effective treatments, resulting in early childhood death. A couple with two affected children presented for reproductive genetic counselling and chose to undertake IVF and preimplantation genetic diagnosis (PGD) to avoid the possibility of another affected child. However, DNA testing revealed only one mutation in the proband inherited from mother. Linkage analysis identified five informative linked short tandem repeat markers to aid the genetic diagnosis. Following IVF, five cleavage-stage embryos were biopsied and blastomeres were first subjected to whole-genome amplification, then a series of down-stream molecular genetic analyses to diagnose TPP1 genotype and finally array comparative genomic hybridization (CGH) to assess the chromosomal ploidy of each embryo. Two unaffected euploid embryos were identified for transfer. One was transferred on day 5 resulting in an ongoing pregnancy. Confirmatory prenatal diagnosis by amniocentesis showed concordance of the embryo and fetal diagnosis. As far as is known, this is the first successful report of PGD for NCL-2 using double-factor PGD with simultaneous single-gene testing and array CGH to identify an unaffected and chromosomally normal embryo for transfer.
Copyright © 2013 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  aneuploid screening; array comparative genomic hybridization; fluorescent PCR; late infantile neuronal ceroid lipofuscinosis; preimplantation genetic diagnosis; whole-genome amplification

Mesh:

Substances:

Year:  2013        PMID: 23768618     DOI: 10.1016/j.rbmo.2013.04.011

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   4.567


  6 in total

1.  Preimplantation Genetic Diagnosis (PGD) for Monogenic Disorders: the Value of Concurrent Aneuploidy Screening.

Authors:  Kara N Goldman; Taraneh Nazem; Alan Berkeley; Steven Palter; Jamie A Grifo
Journal:  J Genet Couns       Date:  2016-06-09       Impact factor: 2.537

2.  Live births after simultaneous avoidance of monogenic diseases and chromosome abnormality by next-generation sequencing with linkage analyses.

Authors:  Liying Yan; Lei Huang; Liya Xu; Jin Huang; Fei Ma; Xiaohui Zhu; Yaqiong Tang; Mingshan Liu; Ying Lian; Ping Liu; Rong Li; Sijia Lu; Fuchou Tang; Jie Qiao; X Sunney Xie
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-28       Impact factor: 11.205

3.  Homozygous missense mutation Arg207Cys in the WEE2 gene causes female infertility and fertilization failure.

Authors:  Xiaoyu Yang; Li Shu; Lingbo Cai; Xueping Sun; Yugui Cui; Jiayin Liu
Journal:  J Assist Reprod Genet       Date:  2019-03-02       Impact factor: 3.412

Review 4.  Recent Insight into the Genetic Basis, Clinical Features, and Diagnostic Methods for Neuronal Ceroid Lipofuscinosis.

Authors:  Konrad Kaminiów; Sylwia Kozak; Justyna Paprocka
Journal:  Int J Mol Sci       Date:  2022-05-20       Impact factor: 6.208

5.  Mutation update: Review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease.

Authors:  Emily Gardner; Mitch Bailey; Angela Schulz; Mikel Aristorena; Nicole Miller; Sara E Mole
Journal:  Hum Mutat       Date:  2019-07-26       Impact factor: 4.878

6.  Successful clinical application of pre-implantation genetic diagnosis for infantile neuroaxonal dystrophy.

Authors:  Yan Hao; Dawei Chen; Guirong Zhang; Zhiguo Zhang; Xiaojun Liu; Ping Zhou; Zhaolian Wei; Xiaofeng Xu; Xiaojin He; Lixian Xing; Mingrong Lv; Dongmei Ji; Beili Chen; Weiwei Zou; Huan Wu; Yajing Liu; Yunxia Cao
Journal:  Exp Ther Med       Date:  2019-12-09       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.